According to Benzinga, equity research analysts at Morgan Stanley increased the target price of Axsome Therapeutics (NASDAQ: AXSM) in a
(NASDAQ: TRSSF) In a report distributed to clients and investors on Wednesday, October 12, stock research analysts lowered their forecasts
Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Rating) has received an average rating of “Buy” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 1-year target price among brokers that
Ayr Wellness Inc. (OTCMKTS:AYRWF - Get Rating) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totalling 569,700 shares, a growth of 31.2% from the September 15th total of 434,100 shares. Based on an average trading vol…
Kohl’s Co. (NYSE:KSS - Get Rating) was the target of a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 13,780,000 shares, a drop of 27.3% from the September 15th total of 18,950,000 shares. Based on an average trading volume of…
According to the information provided by Bloomberg.com, each of the twelve research firms that follow the company has given a
Kohl’s Co. (NYSE:KSS - Get Rating) was the target of a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 13,780,000 shares, a drop of 27.3% from the September 15th total of 18,950,000 shares. Based on an average trading volume of…
TerrAscend Corp. (OTCMKTS:TRSSF - Get Rating) - Equities research analysts at Clarus Securities lowered their FY2023 EPS estimates for TerrAscend in a research report issued to clients and investors on Wednesday, October 12th. Clarus Securities analyst N. Atkinson now expects that the company wil
Canaccord Genuity Group reduced their price target on COMPASS Pathways from $78.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday.
Blucora, Inc. (NASDAQ:BCOR - Get Rating) - Investment analysts at Barrington Research cut their Q3 2022 earnings per share (EPS) estimates for shares of Blucora in a research note issued on Monday, October 10th. Barrington Research analyst A. Paris. Jr now anticipates that the information service
Morgan Stanley raised their price target on Sarepta Therapeutics from $135.00 to $141.00 and gave the company an “equal weight” rating in a research report on Thursday.
Shares of Digi International Inc. (NASDAQ:DGII - Get Rating) have earned an average rating of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation
<p>The “merger of equals” will bring together complementary spine surgery and orthopedic products including spine implants, biologics, limb-reconstruction devices and surgical planning and navigation software.</p>
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Rating) - Stock analysts at Cantor Fitzgerald decreased their FY2022 EPS estimates for BioMarin Pharmaceutical in a research report issued to clients and investors on Wednesday, October 12th. Cantor Fitzgerald analyst O. Brayer now anticipates that
Morgan Stanley raised their price objective on shares of Gilead Sciences from $65.00 to $67.00 and gave the stock an “equal weight” rating in a research report on Thursday.
Morgan Stanley dropped their price objective on Alnylam Pharmaceuticals from $222.00 to $220.00 and set an “equal weight” rating for the company in a research note on Thursday.
Joe Biden’s announcement last week has little effect on the bottom line for marijuana companies, but it raises hopes for more significant reforms on the horizon.
Shares of Veru Inc. (NASDAQ:VERU - Get Rating) have received a consensus recommendation of “Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brok
In In re BGC Partners, Inc. Derivative Litigation, the Delaware Court of Chancery, in a post-trial opinion by Vice Chancellor Will, found BGC…
The Goldman Sachs Group lowered their price objective on shares of Symbotic from $19.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday.